

# Addressing the aftermath of the COVID-19 pandemic: a quality improvement collaborative to optimize the use of antibacterials in Argentine Intensive Care Units.

## Supplementary appendix

eTable 1. Severity of clinical presentation and site of infection origin between study phases.....	2
eTable 2. Illness severity stratified analysis for days of antibacterial treatment. ....	2
eTable 3. Illness severity stratified analysis for antibacterial defined daily doses. ....	3
eTable 4. Distribution of antibacterials, including median doses, reported for each period..	4
eTable 5. Times from microbiological rescue to antibacterial adjustment and prescription between study periods. ....	5
eTable 6. Antibacterial resistance between study periods. ....	5

eTable 1. Severity of clinical presentation and site of infection origin between study phases.

Characteristic	Baseline (N = 547) N (%)	Implementation (N = 812) N (%)	P- value*
<b>Severity of infection</b>			<0.001
Sepsis	173 (31.6%)	293 (36.1%)	
Septic shock	185 (33.8%)	325 (40.0%)	
Infection without sepsis	189 (34.6%)	194 (23.9%)	
<b>Site of infection</b>			0.083
Respiratory infection	229 (41.9%)	321 (39.5%)	
Urinary tract infection	37 (6.8%)	49 (6.0%)	
CNS infection	18 (3.3%)	46 (5.7%)	
Skin and soft tissue infection	45 (8.2%)	74 (9.1%)	
Ventilator-associated pneumonia	114 (20.8%)	149 (18.3%)	
Central venous catheter associated infection	40 (7.3%)	55 (6.8%)	
Urinary catheter-associated infection	22 (4.0%)	21 (2.6%)	
C. difficile colitis	4 (0.7%)	15 (1.8%)	
Primary bacteremia	28 (5.1%)	55 (6.8%)	
Other	10 (1.8%)	27 (3.3%)	

\*Chi-squared test

eTable 2. Illness severity stratified analysis for days of antibacterial treatment.

Strata	Baseline period n/N (per 1,000)	Implementation period n/N (per 1,000)	Ratio of the rates (Post/Pre) (IC 95%)Ω
<b>Sofa score<sup>1</sup></b>			
High (n = 488)	2754 / 2382 (1156.2)	4478 / 4114 (1088.5)	0.97 (0.88;1.08)
Low (n = 424)	2318 / 2093 (1107.5)	3087 / 2688 (1148.4)	1.00 (0.89;1.12)
<b>Apache score<sup>2</sup></b>			
High (n = 436)	2513 / 2177 (1154.3)	4123 / 3633 (1134.9)	0.94 (0.85;1.04)
Low (n = 476)	2559 / 2298 (1113.6)	3442 / 3169 (1086.2)	0.98 (0.93;1.03)
<b>Kidney failure</b>			
Yes (n = 349)	2130 / 1637 (1301.2)	3380 / 2717 (1244.0)	0.99 (0.88;1.11)
No (n = 563)	2942 / 2838 (1036.7)	4185 / 4085 (1024.5)	0.95 (0.86;1.06)
<b>Septic shock</b>			
Yes (n = 389)	2484 / 1895 (1310.8)	4157 / 3350 (1240.9)	0.98 (0.88;1.09)
No (n = 523)	2588 / 2580 (1003.1)	3408 / 3452 (987.3)	0.95 (0.86;1.06)

Ω Intervention impact tested by the Generalized Linear Model

<sup>1</sup> High SOFA score: scores > 5, Low SOFA score: scores <=5

<sup>2</sup> High APACHE score: scores >16, Low APACHE score: scores <=16

n: number of days of antibacterial treatment, N: number of intensive care unit days of stay

eTable 3. Illness severity stratified analysis for antibacterial defined daily doses.

Strata	Baseline period	Implementation period	Ratio of the rates (Post/Pre) (IC 95%) $\Omega$
	n/N (per 1,000)	n/N (per 1,000)	
<b>SOFA<sub>24</sub> score<sup>1</sup></b>			
High (n = 488)	3264 / 2382 (1370.4)	4776 / 4114 (1161.0)	0.86 (0.76; 0.97)
Low (n = 424)	2558 / 2093 (1222.1)	3338 / 2688 (1241.9)	0.89 (0.78; 1.02)
<b>APACHE II score<sup>2</sup></b>			
High (n = 436)	2874 / 2177 (1320.0)	4279 / 3633 (1177.9)	0.87 (0.76; 1.00)
Low (n = 476)	2948 / 2298 (1283.1)	3835 / 3169 (1210.3)	0.88 (0.78; 0.99)
<b>Kidney failure</b>			
Yes (n = 349)	1968 / 1637 (1202.5)	3160 / 2717 (1163.1)	0.93 (0.81; 1.08)
No (n = 563)	3854 / 2838 (1357.8)	4954 / 4085 (1212.8)	0.85 (0.76; 0.95)
<b>Septic shock</b>			
Yes (n = 389)	2815 / 1895 (1485.7)	4269 / 3350 (1274.3)	0.88 (0.77; 1.01)
No (n = 523)	3007 / 2580 (1165.3)	3846 / 3452 (1114.1)	0.85 (0.75; 0.96)

$\Omega$  Intervention impact tested by the Generalized Linear Model

1 High SOFA<sub>24</sub> score: scores > 5, Low SOFA<sub>24</sub> score: scores <=5

2 High APACHE II score: scores >16, Low APACHE II score: scores <=16

n: daily dose of antibiotics, N: number of intensive care unit days of stay

eTable 4. Distribution of antibacterials, including median doses, reported for each period.

Antibacterials	Baseline (N= 357)		Implementation (N = 555)	
	n (%)	Median (Q1-Q3) in mg or IU	N (%)	Median (Q1-Q3) in mg or IU
Amikacina	28 (7.8%)	5 (2-7)	35 (6.3%)	3 (2-6)
Amoxicilina + acido clavulánico	5 (1.4%)	24 (18-36)	2 (0.4%)	16 (9-23)
Ampicilina	8 (2.2%)	49 (40.5-64.975)	15 (2.7%)	48 (24-90)
Ampicilina + Sulbactam	146 (40.9%)	30 (18-41.625)	236 (42.5%)	24 (13.125-36)
Aztreonam	4 (1.1%)	11 (8.8-13.375)	4 (0.7%)	26 (21-28.35)
Bencilpenicilina	1 (0.3%)	1200000*	1 (0.2%)	12500000*
Bencilpenicilina benzatínica	-	-	1 (0.2%)	2400000*
Cefazolina	19 (5.3%)	15 (9-60)	14 (2.5%)	15 (7-27.75)
Cefepime	26 (7.3%)	18 (10.5-30)	30 (5.4%)	18 (12-42)
Cefotaxima	1 (0.3%)	36*	4 (0.7%)	10 (6-18)
Ceftazidima	21 (5.9%)	15 (6-18)	20 (3.6%)	15 (12-27)
Ceftazidima + avibactam	12 (3.4%)	17.5 (14.75-31.25)	12 (2.2%)	31.8 (22.725-40.8)
Ceftriaxona	18 (5.0%)	8 (4.5-14)	43 (7.7%)	12 (4-20)
Ciprofloxacina	11 (3.1%)	2.5 (1.4-4.4)	24 (4.3%)	2.4 (1.5-3.7)
Claritromicina	54 (15.1%)	4 (2-5)	66 (11.9%)	3 (2-5)
Clindamicina	28 (7.8%)	7.8 (3.3-12.6)	32 (5.8%)	7.8 (4.5-11.1)
Colistin	138 (38.7%)	1.4 (0.8-2.1)	250 (45.0%)	1.4 (0.8-2.4)
Doxiciclina	1 (0.3%)	0.4*		
Fosfomicina (intravenosa)	3 (0.8%)	60 (32-86)	10 (1.8%)	56 (28-121)
Gentamicina	11 (3.1%)	1.2 (1-1.4)	11 (2.0%)	1 (0.95-1.8)
Imipenem	11 (3.1%)	9 (6.75-10.25)	12 (2.2%)	6 (3.75-10.625)
Levofloxacina	3 (0.8%)	3.2 (1.85-3.85)	5 (0.9%)	3.5 (2.4-4)
Linezolid	15 (4.2%)	4 (3.6-9.6)	13 (2.3%)	6 (3.6-9.6)
Meropenem	110 (30.8%)	15 (9-24)	170 (30.6%)	18 (12-30)
Meropenem + vaborbactam			1 (0.2%)	126*
Metronidazol	12 (3.4%)	5.25 (4.125-7.5)	24 (4.3%)	6 (1.5-12)
Nitrofurantoina	1 (0.3%)	1.2 (1.2-1.2)	1 (0.2%)	1.4*
Otros	36 (10.1%)	1.65 (0.75-4)	16 (2.9%)	2.2 (0.9-7.2)
Piperacilina + tazobactam	120 (33.6%)	54 (36-82.525)	224 (40.4%)	54 (30.875-90)
Procaína bencilpenicilina			1 (0.2%)	24000000*
Tigeciclina	15 (4.2%)	1 (0.7-1.5)	39 (7.0%)	0.7 (0.4-1.4)
Trimetoprima + sulfametoxzazol	36 (10.1%)	5.15 (2.4-10.5)	19 (3.4%)	3.2 (1.3-4.5)
Vancomicina	127 (35.6%)	6 (4-11)	203 (36.6%)	7.5 (4-12)

\* Since only one observation was recorded, only the observed value is reported.

IU= international units

eTable 5. Times from microbiological rescue to antibacterial adjustment and prescription between study periods.

<b>Characteristic</b>	<b>Baseline</b> (N = 438)	<b>Intervention</b> (N = 587)	<b>P-value*</b>
	<b>n/N (%)</b>	<b>n/N (%)</b>	
<b>Requires antibacterial adjustment</b>	243/438 (55.5%)	292/587 (49.7%)	0.069
<b>Time ranges from microbiological rescue to antibacterial prescription</b>			<0.001
< 24 h	111/233 (47.6%)	181/274 (66.1%)	
24-48 h	86/233 (36.9%)	71/274 (25.9%)	
>48-72 h	26/233 (11.2%)	10/274 (3.6%)	
>72hs	10/233 (4.3%)	12/274 (4.4%)	
Not done	0/233 (0.0%)	0/274 (0.0%)	

\*Chi-squared test used

eTable 6. Antibacterial resistance between study periods.

<b>Characteristic</b>	<b>Baseline</b> (N = 438)	<b>Intervention</b> (N = 587)	<b>P-value*</b>
	<b>n/N (%)</b>	<b>n/N (%)</b>	
<b>Antibacterial resistance</b>	158/438 (36.1%)	210/587 (35.8%)	>0.9
<b>Antibacterial resistance Type</b>			
Methicillin resistance	18/158 (11.4%)	47/210 (22.4%)	0.006
Vancomycin resistance	10/158 (6.3%)	6/210 (2.9%)	0.11
Extended-spectrum beta-lactamase	33/158 (20.9%)	38/210 (18.1%)	0.5
Carbapenemase	48/158 (30.4%)	64/210 (30.5%)	>0.9
<b>Type of carbapenemase</b>			
KPC	31/48 (64.6%)	33/63 (52.4%)	0.2
MBL	22/48 (45.8%)	31/63 (49.2%)	0.7
Others	1/48 (2.1%)	2/63 (3.2%)	>0.9

\*Chi-square test used